Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2010
11/04/2010CA2760392A1 Influenza vaccine
11/04/2010CA2760330A1 Dc-stamp antibodies
11/04/2010CA2760305A1 Ex-vivo treatment of immunological disorders with pkc-theta inhibitors
11/04/2010CA2760098A1 Mutants of francisella tularensis and uses thereof
11/04/2010CA2760096A1 Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder
11/04/2010CA2759989A1 Anti cxcr4 antibodies for the treatment of hiv
11/04/2010CA2759797A1 A novel subtype of clostridium botulinum neurotoxin type a and uses thereof
11/04/2010CA2759792A1 Improved antibodies immunoreactive with heregulin-coupled her3
11/04/2010CA2759400A1 Chimeric factor h binding proteins (fhbp) and methods of use
11/04/2010CA2759280A1 Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
11/04/2010CA2758290A1 Antagonistic activin receptor iib (actriib)antibodies for increasing muscle growth
11/04/2010CA2757638A1 Erg monoclonal antibodies
11/04/2010CA2757620A1 Pneumococcal vaccine and uses thereof
11/04/2010CA2756760A1 Compositions and methods for screening and using compounds antagonizing spore-surface interactions
11/03/2010EP2246430A1 Anti-adam-15 antibodies and utilization of the same
11/03/2010EP2246427A1 Antibody capable of binding specifically to a -oligomer, and use thereof
11/03/2010EP2246426A1 Composition for neutralizing botulinus toxin type-a, and human anti-botulinus toxin type-a antibody
11/03/2010EP2246364A1 Anti CXCR4 antibodies for the treatment of HIV
11/03/2010EP2246363A1 Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
11/03/2010EP2246362A2 Polymer conjugates of mutated neublastin
11/03/2010EP2246361A1 Synthetic peptide constructs for the diagnosis and treatment of periodontitis associated with porphyromonas gingivalis
11/03/2010EP2246067A2 Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
11/03/2010EP2245156A1 Humanized anti- 9 integrin antibodies and the uses thereof
11/03/2010EP2245154A2 Pre-or post-exposure treatment for filovirus or arenavirus infection
11/03/2010EP2245071A1 1d05 pcsk9 antagonists
11/03/2010EP2245070A1 1b20 pcsk9 antagonists
11/03/2010EP2245069A1 Humanized antibodies specific for von willebrand factor
11/03/2010EP2245068A1 Procedure for the generation of a high producer cell line for the expression of a recombinant anti-cd34 antibody
11/03/2010EP2245065A1 Optimized cd40 antibodies and methods of using the same
11/03/2010EP2245062A1 Methods of treating bone-loss disorders using a gm-csf antagonist
11/03/2010EP2245048A2 Meningococcal fhbp polypeptides
11/03/2010EP2244736A1 Ligands of the natural killer (nk) cell surface marker cd27 and therapeutic uses thereof
11/03/2010EP2244735A1 Antibody therapy for use in the digestive tract
11/03/2010EP2244734A2 A method of inducing tolerance to an allergen
11/03/2010EP2244733A2 Immunotherapy targeting intracellular pathogens
11/03/2010EP2244732A1 A truncated form of the hiv p17 protein
11/03/2010EP2244731A2 Canine influenza vaccines
11/03/2010EP2244730A2 Vaccines
11/03/2010EP2244729A1 Cysteine engineered antibodies for site-specific conjugation
11/03/2010EP2244725A1 Novel peptides and protein and uses thereof
11/03/2010EP2244714A1 Use of picoplatin and bevacizumab to treat colorectal cancer
11/03/2010EP2244695A1 Compositions for inducing immune responses
11/03/2010EP2046331B1 Use of 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment of mantle cell lymphomas
11/03/2010EP2009443B1 Diagnostic agent and therapeutic agent for pancreatic cancer
11/03/2010EP1741792B1 Novel ligand of g-protein-conjugated receptor protein and use thereof
11/03/2010EP1725872B1 Analysis of saccharide vaccines without interference
11/03/2010EP1702625B1 Medicine containing genetically modified antibody against chemokine receptor ccr4
11/03/2010EP1674111B1 Anti-glypican 3 antibody
11/03/2010EP1546205B1 Methods for regulating cancer
11/03/2010EP1478664B1 Tissue specific expression
11/03/2010EP1076662B1 Polyepitope carrier protein
11/03/2010EP0938320B9 Method enabling use of extracellular rna extracted from plasma or serum to detect, monitor or evaluate cancer
11/03/2010EP0912734B1 Chimeric heteromultimer adhesins
11/03/2010CN1958074B Injectable block copolymer hydrogel of temperature sensibility(epsi - caprolactone - glycolide)- polyethyleneglycol
11/03/2010CN1895667B Reovirus inactivated vaccine and its preparation
11/03/2010CN1551783B Use of analog K121 antibody in preparing medicine for K type multiple myeloma
11/03/2010CN1368888B Anti-human mitochondrial a denylate kinase isozyme antibody, diagnostic formulation and diagnostic kit for cardiac disease
11/03/2010CN101878302A Pseudomonas aeruginosa outer membrane protein PA4710
11/03/2010CN101878301A Antibody and use thereof
11/03/2010CN101878229A Immunoliposomes for treatment of cancer
11/03/2010CN101878228A Human monoclonal nicotine specific antibodies
11/03/2010CN101878038A Engineered pertactin variants for vaccine use
11/03/2010CN101878037A Use of human antibody capable of neutralizing hepatitis b virus for the prevention or treatment of hepatitis b virus infection
11/03/2010CN101878036A A pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
11/03/2010CN101875920A DcR3 (Decoy Receptor 3) and GAD65 (Glutamic Acid Decarboxylase 65) double gene co-expression recombinant adenovirus as well as preparation method and application thereof
11/03/2010CN101875913A Recombinant mycobacterium smegmatis strain capable of expressing mycobacterium tuberculosis Ag 85B and ESAT-6 fusion protein and application thereof
11/03/2010CN101875697A Design of novel anti-EGFR humanized antibody TGM10 and application thereof
11/03/2010CN101875696A Antibody, and preparation method and application thereof
11/03/2010CN101875695A Antibody, and coding gene and application thereof
11/03/2010CN101875694A Antibody of TNF (Tumor Necrosis Factor) alpha and application thereof
11/03/2010CN101874898A General trivalent gene recombination vaccine for preventing infection of leptospira interrogans of different sero-groups and preparation method thereof
11/03/2010CN101874897A Immunomodifier for reducing blood total cholesterol and administration method thereof
11/03/2010CN101014619B Optimized fc variants
11/02/2010US7825225 Vaccine
11/02/2010US7825219 Binding protein; therapy for bone tumors
11/02/2010US7825097 Nucleotide vector vaccine for immunization against hepatitis
11/02/2010US7825088 Methods for the treatment of multiple myeloma
11/02/2010US7824908 Expression vector comprising nucleotide sequences coding toxoplasma major surface antigen p30 for use in generation of immunoglobulin for use in prevention and treatment of parasitic infection
11/02/2010US7824907 Expression vectors comprising the mCMV IE2 promoter
11/02/2010US7824849 determining whether a target cell expresses telomerase reverse transcriptase (TRT) by combining human T lymphocytes ex vivo with antigen-presenting cells containing a polypeptide that comprises at least 8 consecutive amino acids of telomerase reverse transcriptase
11/02/2010US7824696 Modified nucleotides for immunotherapy; induce immunology response; consisting of nucleoside methylphosphonate and 2'-O-methyl-ribonucleoside groups
11/02/2010US7824695 recombinant proteins comprise cell recognition moiety that binds alpha 2 macroglobulin receptor, and bioactive moiety (pseudomonas exotoxin), which mediates systemic effect, does not function as immunogen and does not have ADP ribosylating activity
11/02/2010US7824694 decreasing dose of headache medication (acetaminophen) via titration process in reverse of dosing regimen, locally administering botulin toxin; pharmacokinetics
11/02/2010US7824693 administering Botulinum toxin
11/02/2010US7824692 homologous immunoreactive thio-disulfide oxidoreductases; fusion proteins; fluorescent, radioactive, or enzymatic labels
11/02/2010US7824691 RNAIII-inhibiting peptide (RIP) with antimicrobial peptide such as cathelicidin, capable of binding and neutralizing lipidic and polyanionic components of bacterial cell envelope; infections from Staphylococcus and Bacillus; antibiotic resistance; cellulitis, keratitis, osteomyelitis, septic arthrititis
11/02/2010US7824690 oncogenes; low pathogenicity
11/02/2010US7824689 immunogens; immunololgy; for production of vaccines; able to induce antiserum having neutralizing antibody; neutralization assay; Mareks Disease virus, infectious bronchitis virus, Newcastle disease virus, egg drop syndrome virus, turkey rhinotracheitis virus, or reovirus
11/02/2010US7824688 Glucan-based vaccines
11/02/2010US7824687 Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
11/02/2010US7824686 Vaccines with enhanced immune response and methods for their preparation
11/02/2010US7824685 related to testes-specific, vespid and pathogenic proteins (RTVP); metastatic prostatic neoplasia
11/02/2010US7824684 Contain an Fc part derived from human origin and do not bind complement factor C1q; for inflammatory and thrombotic disorders such as critical limb ischemia or peripheral arterial occlusive disease; atherosclerosis, thrombosis, restenosis, asthma, arthritis
11/02/2010US7824683 Methods for augmenting an immune response using anti-CD40 antibodies
11/02/2010US7824682 Dna sequence and genomic structure of human cardiac isoform; gene or allele mutants associated with cardiovascular disorders; reduce stretch activation and adjust tension of muscles in heart contraction; isolated nucleic acid encoding a protein
11/02/2010US7824681 Specifically binds insulin-like growth factor II (IGF-II) with equilibrium dissociation constant (Kd) of 1 nM or less where antibody binds IGF-I with equilibrium dissociation constant (Kd) of 1 mM or greater, and where antibody inhibits phosphorylation of insulin-like growth factor receptor
11/02/2010US7824680 Methods for inhibiting angiogenesis
11/02/2010US7824679 Complementarity determining regions; immunoglobulins; cell line, host cells; transgenic animals, plants
11/02/2010US7824678 Antibodies against cancer antigen TMEFF2 and uses thereof
11/02/2010US7824677 inhibiting blood coagulation mediated by factor X binding to tissue factor; provide superior anti-coagulant activity by binding native human tissue factor with high affinity and specificity; linked covalently to a cell antigen or an effector molecule to provide complement fixing ability
1 ... 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 ... 1823